|
22.01.2018 03:21:14
|
WSJ : Sanofi Nears Deal To Buy Bioverativ For More Than $11.5 Bln
(RTTNews) - Sanofi SA (SNYNF, SNY) is nearing a deal to buy hemophilia drugmaker Bioverativ Inc. (BIVV) for more than $11.5 billion as the French drugmaker looks set to clinch a big deal while it braces for generic competition for its top-selling product, the Wall Street Journal reported citing people familiar with the matter
A deal, which could be announced as soon as Monday, would value the former Biogen Inc. unit at $105 a share. The price would represent a 63% premium to where Bioverativ closed trading Friday. It is possible the talks could fall apart before a deal is reached, the Journal reported.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Biogen Incmehr Nachrichten
Analysen zu Biogen Incmehr Analysen
Aktien in diesem Artikel
| Biogen Inc | 152,65 | -0,46% |
|
| Sanofi S.A. (spons. ADRs) | 45,60 | 0,88% |
|
| Sanofi S.A. | 91,57 | -0,24% |
|
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.